Drug Database
NE
nepafenac (Ilevro)
✓ ApprovedAlcon, Inc. · PTGS1 · Small Molecule
What is nepafenac?
nepafenac is a small molecule developed by Alcon, Inc.. It is approved for therapeutic indications via others.
Drug Profile
| Brand Names | Ilevro |
| Company | Alcon, Inc. |
| Drug Class | Small Molecule |
| Molecular Target | PTGS1, PTGS2 |
| Route | Others |
| Status | Approved |
Sources: ClinicalTrials.gov, Alcon, Inc.
Mechanism of Action
Molecular Targets
nepafenac acts on 2 molecular targets:
| PTGS1 | prostaglandin-endoperoxide synthase 1 (COX3, PCOX1) |
| PTGS2 | prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
nepafenac is developed for 3 unique indications across 2 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Eye disorders | Diabetic retinal oedema | ✓ Approved |
| Eye disorders | Cataract | ✓ Approved |
| Injury, poisoning and procedural complications | Procedural pain | ✓ Approved |
Related Research Articles
Unable to load articles right now.